Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Viktor Chirikov
Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real-World Effectiveness of Brentuximab Vedotin Versus Physicians’ Choice Chemotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the United Kingdom and Germany
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
Related publications
Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England
Journal of Medical Economics
Health Policy
Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Pnd57 - The Cost-Effectiveness of Alemtuzumab in the Management of Relapse-Remitting Multiple Sclerosis in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd65 - Cost-Effectiveness Analysis of Drugs Used for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd66 - Cost Effectiveness Analysis of Alemtuzumab as a Treatment Option for Patients With Multiple Sclerosis in Cyprus
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd59 - Cost Effectiveness Analysis of Alemtuzumab as a Treatment Option for Patients With Multiple Sclerosis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
Journal of Managed Care Pharmacy
